We’re cutting edge innovators pioneering next-generation therapies for life-changing conditions. We are the minds behind the Vivally® System, a patient-friendly, smart wearable bladder control therapy and mobile app for women and men with urge urinary incontinence and urinary urgency without the need for surgery, implants or drugs.
John is a highly accomplished medical sales executive with an extensive background in healthcare and a strong track record of achievement. Throughout his career, John has consistently demonstrated his ability to develop and execute successful sales strategies, manage multimillion-dollar accounts and budgets, and provide valuable guidance to C-level executives, physicians, and clinical staff. With experience selling biologics, regenerative medicine, orthopedics, and capital equipment. His innovative thinking and deep industry knowledge have earned him a reputation for driving double-digit revenue growth year over year.
John holds an MBA from Cleveland State University and a Bachelor of Science in Business Administration from Edinboro University of Pennsylvania. His exceptional leadership skills, innovation, and ability to drive revenue growth make him a valuable asset in medical sales.
John resides in Texas.
Jennifer Estep serves Avation Medical as Vice President of Product Marketing & Customer Care, bringing more than 20 years of experience in global marketing, commercial launch, strategic communications, and more than 10 years of medtech and pharmaceutical industry experience, successfully bringing best-in-class solutions to market to benefit patients.
Driven by her passion to advance world-class medtech innovation to benefit patients in need, Jennifer brings experience successfully commercializing a first-in-class combination product, building high-impact teams, communicating strategic life-improving innovations, and delivering solutions through internal and external collaborative partnerships. Jennifer is motivated to make a difference for patients and redefine the patient experience for the benefit of people worldwide.
Jennifer earned a bachelor’s in science in Mechanical Engineering from Purdue University and has studied marketing, competitive strategy, and business communications at Harvard University.
Mr. Hoffman is a results-driven market access professional with extensive industry relationships and experience in securing medical policy and in-network access within both commercial and government health insurance industries. In his numerous roles, he has demonstrated a track record of successful product launches and development. Michael’s leadership has resulted in enhanced coverage, greater patient access and improved average sales price..
Michael excels at networking and working across organizations ensuring that a company’s product portfolio is properly represented. Michael attended the University of South Carolina, where he was cross country and track athlete. Michael graduated from Northern Illinois University with a BS in History and Sociology.
Marshal joined the Avation Medical Board in 2024. Marshal has been involved in medical device innovation for over 25 years. Among other projects, Marshal led the development and commercialization of the ZOLL LifeVest, the first and only wearable defibrillator for patients at risk of sudden cardiac death. He continues to work with Asahi Kasei/ZOLL Medical to support business development efforts. Prior to this, he held a wide range of positions with IBM, with responsibilities including hardware and software development, industrial design, systems integration, and new business development. Marshal holds MS and BS degrees in electrical and computer engineering as well as a BS in physics from Clarkson University, and is an inventor on 14 US patents
Thomas joined the Avation Medical Board in 2024 and is currently a Senior Principal at Angelini Ventures, leading investments in life sciences companies. In addition to his role board role at Avation Medical, he is currently a Board Director of Damona Pharmaceuticals, and board member of Arclight Therapeutics, GenEP and Cadence Neuroscience.
Thomas is passionate about life sciences, technology and entrepreneurship. He has 15 years of experience in research, health tech and the pharma industry. Prior to joining Angelini Ventures, Thomas worked for Lundbeck as Director of Corporate Business Development and Strategy. In this role, he was responsible for the in-licensing of therapeutic assets in the CNS space. In addition, he led strategic projects such as Lundbeck’s Global Corporate Digital Strategy and business development for digital health. Previously, Thomas was an Associate Director for Global Business Development at UCB Pharma in Belgium, where he worked on out-licensing as well as strategic investments in the field of digital health. Thomas is also a co-founder of Jymmin, a Max Planck Health-Tech spin-off in Germany and VUS Dx, an oncology diagnostics company in The Netherlands.
Early in his career, Thomas worked as an Associate for Sunstone Life Science Ventures, a Danish Venture Capital fund based in Copenhagen. At Sunstone, Thomas invested in life science innovations such as drug development, medtech and diagnostics. Prior to joining Sunstone, Thomas worked as a Life Science consultant for the Innovation Centre Denmark in Munich, where he assisted Danish biotechnology, pharma, and MedTech start-ups and SMEs operating in the German and Swiss markets.
Thomas received his Ph.D. from the Max Planck Institute of Neurobiology and Ludwig Maximilian University in Munich, Germany, and worked as a visiting researcher at the Janelia Farm Research Campus of the Howard Hughes Medical Institute (HHMI) in Virginia.
The University of Copenhagen awarded him a Master of Science and a Bachelor of Science in Biology and Biotechnology, with experimental work at the University of Queensland, Australia.
Chris joined the Avation team as a Board Observer in 2024 and is currently an Investment Director in Asahi Kasei’s corporate venture capital fund, leading all aspects of investment diligence and portfolio management for AK’s medtech, biotech, and digital health investments, and connecting companies to the resources and expertise of AK’s business units. Prior to AK, Chris worked in life sciences strategy consulting at Clarion Healthcare and business development at BridgeBio. A native Minnesotan, Chris received his BA in Biology and Economics from Williams College and his MBA in healthcare management from The Wharton School.
Charity Tarn joined the Avation Medical Board as an Observer in September 2022.
Charity is currently with Arboretum Ventures and is responsible for evaluating new investment opportunities and supporting Arboretum’s portfolio companies. Prior to joining Arboretum, Charity was a Senior Manager in Medtronic’s Corporate Development team where she executed M&A transactions across all portfolios and led enterprise level strategic initiatives. She also held Corporate Finance and Corporate Strategy roles at Cardinal Health. Charity currently serves as a Board Member for SonarMD and is a Board Observer for Motif Neurotech, Reprieve Cardiovascular, Virtual Incision, and Akadeum Life Sciences.
Charity earned her BA in Psychology and BBA from the University of Michigan and an MBA from Harvard Business School.
My LinkedIn:
https://www.linkedin.com/in/chartarn/